Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NOUS-209 (GAd20-209-FSP) is an off-the-shelf cancer immunotherapy for MSI-H tumors. MSI-H tumors are characterized by a defective DNA mismatch repair system, which generates highly immunogenic neoantigens called frame shift peptides that are not present in healthy tissue.
Lead Product(s): GAd20-209-FSP,MVA-209-FSP,Pembrolizumab
Therapeutic Area: Oncology Product Name: NOUS-209
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: Nouscom AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 05, 2023
Details:
Under the agreement, PeptiDream will provide peptide candidates identified from PeptiDream’s proprietary Peptide Discovery Platform System (“PDPS”) technology for use as PDCs against targets of interest to MSD.
Lead Product(s): Peptide-drug Conjugate
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Peptide
Recipient: PeptiDream
Deal Size: $2,100.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 27, 2022
Details:
ATG-037 is an oral, small molecule CD73 inhibitor. CD73 generates adenosine, which leads to immunosuppression in the tumor microenvironment. ATG-037 has demonstrated promising preclinical efficacy as a monotherapy and in combination with ICIs and chemotherapy agents.
Lead Product(s): ATG-037,Pembrolizumab
Therapeutic Area: Oncology Product Name: ATG-037
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Antengene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 26, 2022
Details:
Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumours harbouring a deficiency in HRR, such as those with mutations in BRCA1 and/or BRCA2, or those where deficiency is induced by other agents.
Lead Product(s): Olaparib,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
DR30303 is a humanized anti-Claudin18.2 heavy chain antibody Fc fusion protein (VHH-Fc) generated via Doer Biologics' proprietary SMART-VHHBody platform.
Lead Product(s): DR30303,Pembrolizumab
Therapeutic Area: Oncology Product Name: DR30303
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Zhejiang Doer Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 15, 2022
Details:
LYNPARZA (olaparib), is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells.
Lead Product(s): Olaparib,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
PMC-309 is a novel IgG1 anti-VISTA antagonizing antibody that can be used for the treatment of various tumor types. By inhibiting VISTA, it can play a pivotal role in maintaining the immunosuppressive environment around the tumor cells.
Lead Product(s): PMC-309,Pembrolizumab
Therapeutic Area: Oncology Product Name: PMC-309
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: PharmAbcine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 12, 2022
Details:
VB10.16 is an off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. Under the terms of the agreement, Merck will supply KEYTRUDA. Nykode retains all commercial rights to VB10.16 worldwide.
Lead Product(s): VB10.16,Pembrolizumab
Therapeutic Area: Oncology Product Name: VB10.16
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Nykode Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 06, 2022
Details:
Lynparza (olaparib) is first-in-class PARP inhibitor and first targeted treatment to block DNA damage response in cells/tumours harboring deficiency in HRR.
Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
The approval by CNMPA was based on HRD-positive subgroup exploratory analysis of PAOLA-1 Phase III trial which showed Lynparza (olaparib) plus bevacizumab demonstrated a substantial PFS improvement versus bevacizumab for patients with HRD-positive advanced ovarian cancer.
Lead Product(s): Olaparib,Bevacizumab
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2022